Clinical Trial

Study of BLU-808 in Allergic Rhinoconjunctivitis

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-03; most recent amendment 2026-02-07.
Status change: Active, Not Recruiting → Completed 2026-02-07
Status change: Recruiting → Active, Not Recruiting 2025-12-05
Status change: Not Yet Recruiting → Recruiting 2025-04-29
Trial Details
NCT Number NCT06922448
Lead Sponsor Blueprint Medicines Corporation
Conditions Allergic Rhinoconjunctivitis
Enrollment 21 participants
Start Date 2025-04-14
Primary Completion 2025-09-08 (estimated)
Study Completion 2025-09-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-10